Unicycive Therapeutics, Inc. (UNCY)

Over the past six months, Unicycive Therapeutics' stock price has fluctuated. The stock saw a +3.62% increase on November 25, 2025, and a -2.31% change on December 29, 2025. On January 29, 2026, the FDA accepted the Oxylanthanum Carbonate (OLC) New Drug Application (NDA) resubmission, followed by a -4.99% change in stock price. The company participated in a fireside chat at Guggenheim's Emerging Outlook: Biotech Summit on February 4, 2026, with the stock decreasing by -5.92%. On March 30, 2026, the company announced its full-year 2025 financial results and provided a business update, leading to a -4.38% change in stock price. A director, Gaurav Aggarwal, stepped down from the board on April 6, 2026. Unicycive Therapeutics presented at the 25th Annual Needham Virtual Healthcare Conference on April 9, 2026, and the stock increased by +3.10%. An announcement was made on May 1, 2026, regarding the Annual General Meeting scheduled for June 19, 2026. The stock's 52-week range has been between $3.71 and $11.00.

There is no specific information available to indicate demand seasonality for Unicycive Therapeutics, Inc.'s investigational products or services. As a clinical-stage biotechnology company with products still under regulatory review and not yet widely commercialized, typical demand seasonality patterns for established pharmaceutical products would not yet apply.

Unicycive Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for kidney diseases. Their lead product, Oxylanthanum Carbonate (OLC), is being developed for hyperphosphatemia in chronic kidney disease patients on dialysis, aiming for a reduced-pill protocol. The company's second treatment, UNI-494, is for acute kidney injury and has Orphan Drug Designation for preventing Delayed Graft Function in kidney transplant patients.

Unicycive Therapeutics, Inc. primarily focuses on the United States market, identifying, developing, and commercializing therapies to address unmet medical needs. The company is headquartered in Los Altos, California, with another contact address in Mountain View, California. There is potential for OLC beyond domestic borders in price-sensitive economies, particularly in Asia and Latin America.

Unicycive Therapeutics has received a consensus recommendation of "Moderate Buy" from analysts, with five analysts assigning a "buy" rating and one a "sell" rating. The average 12-month target price among brokerages is $24.75. Weiss Ratings reiterated a "sell (d-)" rating on shares of Unicycive Therapeutics on March 27, 2026, and Westpark Capital initiated coverage with a "buy" rating on February 19, 2026. In late 2025, the company held a Type A meeting with the FDA to discuss the resolution of deficiencies cited by the FDA regarding its manufacturing vendor for OLC, and the NDA for OLC was resubmitted in late December 2025 after progress in resolving these deficiencies. In June 2025, the FDA rejected the oxylanthanum carbonate application and flagged issues related to the kidney drug application, which caused the shares to slide.

Unicycive Therapeutics, Inc. has 41 institutional owners and shareholders holding a total of 8,167,548 shares. Major institutional owners include Vivo Capital, LLC, Millennium Management Llc, Octagon Capital Advisors LP, Nantahala Capital Management, LLC, Great Point Partners Llc, Vanguard Group Inc, Logos Global Management LP, Citadel Advisors Llc, Cantor Fitzgerald, L. P., and Geode Capital Management, Llc. Institutional ownership accounts for approximately 49.2% of the company, while individuals hold about 6.6%.